Clinical Trials Logo

Clinical Trial Summary

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, when administered alone and in combination with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and will be assigned to receive monotherapy (KRT-232 alone) or combination therapy (KRT-232 with LDAC or KRT-232 with Decitabine).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04113616
Study type Interventional
Source Kartos Therapeutics, Inc.
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date September 25, 2019
Completion date September 27, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05241106 - A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT05241093 - A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT02074839 - Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation Phase 1
Terminated NCT05345938 - A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT03218683 - Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. Phase 1